DAWN
Day One Biopharmaceuticals, Inc.
$21.53
+0.00
(+0.00%)
Mkt Cap
2.22B
Volume
0
52W Range
5.635-21.53
Sector
Healthcare
Beta
-1.75
EPS (TTM)
-1.04
P/E Ratio
-8.96
Revenue (TTM)
158.18M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 158.18M | 131.16M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (107.32M) | (95.50M) | (188.92M) | (142.18M) | (70.64M) | (40.51M) | (12.63M) |
| EPS | -1.04 | -1.02 | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| Free Cash Flow | (104.08M) | (80.28M) | (150.08M) | (109.90M) | (56.54M) | (13.58M) | (4.51M) |
| FCF / Share | -1.01 | -0.86 | -1.88 | -1.68 | -0.91 | -0.22 | -0.07 |
| Operating CF | (103.76M) | (78.11M) | (146.85M) | (109.87M) | (48.54M) | (13.49M) | (4.51M) |
| Total Assets | 507.83M | 582.79M | 376.05M | 349.06M | 289.82M | 45.66M | 27.34M |
| Total Debt | 2.79M | 2.60M | 408,000 | 813,000 | 220,000 | 402,000 | 0 |
| Cash & Equiv | 197.08M | 124.97M | 230.78M | 85.26M | 284.31M | 43.73M | 27.33M |
| Book Value | 441.16M | 502.75M | 346.54M | 332.04M | 281.15M | 37.76M | (10.67M) |
| Return on Equity | -0.24 | -0.19 | -0.55 | -0.43 | -0.25 | -1.07 | N/A |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.72M | 39.80M | 33.91M | 30.76M | 29.21M | 93.76M | 8.19M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (21.28M) | (19.73M) | (30.32M) | (36.00M) | (65.71M) | 37.04M | (4.41M) | (62.41M) | (54.51M) | (46.15M) | (45.86M) | (42.39M) |
| EPS | -0.21 | -0.19 | -0.29 | -0.35 | -0.70 | 0.38 | -0.05 | -0.72 | -0.62 | -0.54 | -0.61 | -0.49 |
| Free Cash Flow | (17.65M) | (5.80M) | (21.31M) | (62.81M) | (31.43M) | (4.97M) | (66.25M) | (49.73M) | (41.38M) | (40.10M) | (42.58M) | (26.01M) |
| FCF / Share | -0.17 | -0.06 | -0.21 | -0.61 | -0.34 | -0.05 | -0.76 | -0.57 | -0.47 | -0.47 | -0.57 | -0.36 |
| Operating CF | (14.15M) | (5.80M) | (24.81M) | (59.00M) | (30.01M) | 50.75M | (49.13M) | (49.73M) | (41.37M) | (37.06M) | (42.43M) | (25.98M) |
| Total Assets | 507.83M | 513.78M | 519.04M | 534.36M | 582.79M | 600.81M | 400.44M | 326.64M | 376.05M | 414.18M | 450.76M | 323.56M |
| Total Debt | 2.79M | 2.89M | 3.00M | 2.92M | 2.60M | 2.62M | 190,000 | 300,000 | 408,000 | 514,000 | 618,000 | 717,000 |
| Cash & Equiv | 197.08M | 43.28M | 35.62M | 33.36M | 124.97M | 422.76M | 239.62M | 270.39M | 230.78M | 241.18M | 189.21M | 49.27M |
| Book Value | 441.16M | 450.87M | 460.83M | 479.51M | 502.75M | 555.46M | 306.73M | 296.81M | 346.54M | 389.63M | 426.05M | 300.42M |
| Return on Equity | -0.05 | -0.04 | -0.07 | -0.08 | -0.13 | 0.07 | -0.01 | -0.21 | -0.16 | -0.12 | -0.11 | -0.14 |
DAWN News
Servier completes the acquisition of Day One Biopharmaceuticals
Servier finalise l'acquisition de Day One Biopharmaceuticals
Servier completes the acquisition of Day One Biopharmaceuticals
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High – What’s Next?
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More
Are DAWN and TALK Obtaining Fair Deals for their Shareholders?